MNMD

Mind Medicine Inc

MNMD, USA

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

https://www.mindmed.co

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MNMD
stock
MNMD

MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations MSN

Read more →
MNMD
stock
MNMD

CEO Change: Is MNMD stock recession proof - July 2025 PreEarnings & AI Forecast Swing Trade Picks moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$25.6364

Analyst Picks

Strong Buy

7

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.52

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-51.51 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-28.39 %

Low 2%

High 10%

Debt to Equity

-

Low

0.81

Low 1

High 0.3

Investors

* Institutions hold a combined 58.78% of the total shares of Mind Medicine Inc

1.

BlackRock Inc

(7.6256%)

since

2025/06/30

2.

COMMODORE CAPITAL LP

(6.5713%)

since

2025/06/30

3.

Blackstone Inc

(4.7149%)

since

2025/06/30

4.

Marshall Wace Asset Management Ltd

(4.4964%)

since

2025/06/30

5.

Driehaus Capital Management LLC

(4.0646%)

since

2025/06/30

6.

Deep Track Capital, LP

(3.2857%)

since

2025/06/30

7.

Octagon Capital Advisors LP

(2.7994%)

since

2025/06/30

8.

iShares Russell 2000 ETF

(2.4077%)

since

2025/08/31

9.

Vanguard Group Inc

(2.3841%)

since

2025/06/30

10.

State Street Corp

(2.3734%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.2782%)

since

2025/06/30

12.

Awm Investment Company Inc

(1.5977%)

since

2025/06/30

13.

Fidelity Small Cap Index

(0.9957%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9656%)

since

2025/07/31

15.

Ally Bridge Group (NY) LLC

(0.9544%)

since

2025/06/30

16.

Heptagon Driehaus US Micro Cap Eq C$ Acc

(0.9236%)

since

2025/07/31

17.

Morgan Stanley - Brokerage Accounts

(0.9049%)

since

2025/06/30

18.

TANG CAPITAL MANAGEMENT LLC

(0.7888%)

since

2025/06/30

19.

Northern Trust Corp

(0.7876%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.7862%)

since

2025/06/30

21.

UBS Group AG

(0.6761%)

since

2025/06/30

22.

Woodline Partners LP

(0.66%)

since

2025/06/30

23.

iShares Russell 2000 Value ETF

(0.6062%)

since

2025/08/31

24.

Rosalind Advisors, Inc.

(0.552%)

since

2025/06/30

25.

Fidelity Extended Market Index

(0.4857%)

since

2025/07/31

26.

Vanguard Russell 2000 ETF

(0.4719%)

since

2025/07/31

27.

Schwab US Small-Cap ETF™

(0.4296%)

since

2025/08/30

28.

Driehaus Micro Cap Growth USD

(0.3632%)

since

2025/07/31

29.

State St Russell Sm Cap® Indx SL Cl I

(0.3541%)

since

2025/08/31

30.

Wellington Management Company LLP

(0.3443%)

since

2025/06/30

31.

iShares Russell 2000 Growth ETF

(0.2769%)

since

2025/08/31

32.

SPDR® S&P Pharmaceuticals ETF

(0.2762%)

since

2025/08/31

33.

Schwab Small Cap Index

(0.2527%)

since

2025/07/31

34.

Vanguard Health Care ETF

(0.2449%)

since

2025/07/31

35.

iShares US Pharmaceuticals ETF

(0.2403%)

since

2025/08/31

36.

NT R2000 Index Fund - NL

(0.2396%)

since

2025/06/30

37.

iShares Micro-Cap ETF

(0.2244%)

since

2025/08/31

38.

NT R2000 Index Fund - DC - NL - 3

(0.191%)

since

2025/06/30

39.

Extended Equity Market Fund K

(0.1813%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.5233

Latest Release

Date

2025-09-30

EPS Actual

-0.78

EPS Estimate

-0.5

EPS Difference

-0.28

Surprise Percent

-56%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.